Nurix therapeutics to present at 42nd annual j.p. morgan healthcare conference

San francisco, jan. 02, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that arthur t. sands, m.d., ph.d., president and chief executive officer of nurix, will present an overview of nurix's achievements in 2023 and major goals for 2024 at the 42nd annual j.p. morgan healthcare conference on monday, january 8, 2024, at 3:00 p.m. pt.
NRIX Ratings Summary
NRIX Quant Ranking